1. Introduction
Racotumomab [1] is a monoclonal antibody (Mab) of murineanti-idiotype (Ab2) generated by immunizing BALB/c mice withthe P3 monoclonal antibody [2],
a Mab (Ab1) that specifically recognizes N-glycolylated gangliosides, sulfated glycolipids, andantigens present in various types of human tumors includingthose located in lung [3–7].
We hypothesize that RacotumomabMab contains a structural mimicry of ganglioside N-glycolyl GM3(NeuGc-GM3).
The vaccine formulation of Racotumomab/aluminais capable of inducing antitumor effects in murine models [7]
.Among the observed antitumor effects in the murine model accounta decrease in metastases, increased apoptosis of metastatic cells